TY - JOUR
T1 - Ibrutinib-Related Uveitis in Non-Hodgkin Lymphoma Patients
T2 - A Case Report and Literature Review
AU - Mendez, Rafael
AU - Pineda-Sierra, Juan Sebastián
AU - Romero-Santos, Sofia
AU - Cifuentes-González, Carlos
AU - Bonaccorso, Silvina
AU - Couto, Cristobal
AU - Schlaen, Ariel
AU - Mejía-Salgado, Germán
AU - de-la-Torre, Alejandra
N1 - Publisher Copyright:
© 2024 Taylor & Francis Group, LLC.
PY - 2024
Y1 - 2024
N2 - Purpose: To report two cases of ibrutinib-related uveitis and review the literature to date. Methods: We report two cases of ibrutinib-related uveitis using CARE guidelines and review the cases reported in the literature. Results: Case 1) A 55-year-old female with recurrent primary central nervous system lymphoma presented with bilateral decreased visual acuity, photophobia, and floaters that started one month after initiating oral treatment with ibrutinib. Chronic non-granulomatous bilateral anterior-intermediate uveitis with macular edema was identified. Secondary causes were ruled out, and a presumptive diagnosis of ibrutinib-related uveitis was made. Case 2) A 57-year-old female with Waldenström macroglobulinemia who was treated with ibrutinib for two years presented with bilateral blurred vision, photophobia, red eyes, and floaters. A diagnosis of non-granulomatous, noninfectious panuveitis with bilateral cystoid macular edema was made. Secondary causes were ruled out, and ibrutinib toxicity was the most likely cause. Conclusion: Ibrutinib-related uveitis is a novel and under-diagnosed clinical entity. The most frequent clinical presentation in the literature is bilateral, non-granulomatous, anterior, and intermediate uveitis. Macular edema is a frequent complication. Uveitis usually requires topical treatment and the suspension of ibrutinib. Switching to second-generation Bruton tyrosine kinase inhibitors is proposed as a potential therapeutic alternative.
AB - Purpose: To report two cases of ibrutinib-related uveitis and review the literature to date. Methods: We report two cases of ibrutinib-related uveitis using CARE guidelines and review the cases reported in the literature. Results: Case 1) A 55-year-old female with recurrent primary central nervous system lymphoma presented with bilateral decreased visual acuity, photophobia, and floaters that started one month after initiating oral treatment with ibrutinib. Chronic non-granulomatous bilateral anterior-intermediate uveitis with macular edema was identified. Secondary causes were ruled out, and a presumptive diagnosis of ibrutinib-related uveitis was made. Case 2) A 57-year-old female with Waldenström macroglobulinemia who was treated with ibrutinib for two years presented with bilateral blurred vision, photophobia, red eyes, and floaters. A diagnosis of non-granulomatous, noninfectious panuveitis with bilateral cystoid macular edema was made. Secondary causes were ruled out, and ibrutinib toxicity was the most likely cause. Conclusion: Ibrutinib-related uveitis is a novel and under-diagnosed clinical entity. The most frequent clinical presentation in the literature is bilateral, non-granulomatous, anterior, and intermediate uveitis. Macular edema is a frequent complication. Uveitis usually requires topical treatment and the suspension of ibrutinib. Switching to second-generation Bruton tyrosine kinase inhibitors is proposed as a potential therapeutic alternative.
UR - http://www.scopus.com/inward/record.url?scp=85182148356&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85182148356&partnerID=8YFLogxK
U2 - 10.1080/09273948.2023.2295540
DO - 10.1080/09273948.2023.2295540
M3 - Article
AN - SCOPUS:85182148356
SN - 0927-3948
JO - Ocular Immunology and Inflammation
JF - Ocular Immunology and Inflammation
ER -